Solid Tissue Oncology

Molecular Tissue Analysis: PCR-based assays

In addition to a broad range of immunohistochemical and in situ hybridization biomarker assays, we currently offer the following RT-PCR assays for mutation detection in paraffin-embedded tumour samples:

  •  KRAS testing in metastatic colorectal carcinoma
  •  EGFR testing in non-squamous, non-small cell lung carcinoma
  •  BRAF testing in melanoma and colorectal carcinoma

These assays are funded by Medicare if certain criteria are met; details are provided in the SydPath Cancer Genetics Molecular Biomarker Charges Form click here

To Contact the Molecular Oncology Laboratory please call (02) 8382 9156


Paraffin in situ hybridization [ISH] service

Our Paraffin ISH Testing Laboratory [including the National HER2 Reference Laboratory] has vast experience in the application of in situ hybridization assays [both fluorescence and chromogenic] to paraffin embedded tissue sections, receiving referrals from local, interstate and Pacific regional laboratories. Our high test volume enables rapid turn around times.

Available ISH assays include:

  •  HER2 SISH in breast cancer (Medicare funded)
  •  HER2 SISH in advanced gastric and gastro-oesophageal cancers (currently unfunded)
  •  HER2 FISH in breast and gastric carcinomas non-diagnostic by SISH assays (respectively funded by Medicare and unfunded)
  •  Analysis of 1p/19q loss and EGFR amplification in gliomas
  •  Detection of ALK rearrangement in lung cancer (correlated with immunohistochemistry)
  •  Detection of MET amplification in lung cancer
  •  Detection of ROS1 rearrangement in lung cancer

We also work collaboratively with the Cytogenetics department to assess chromosomal rearrangements by FISH in a range of sarcomas and haematological malignancies.

To contact the Paraffin ISH lab phone (02) 8382 9156


To view our Pathologists please click here

To download our Request forms please click here

To download our latest brochures please click here